NCT06957626 Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy
| NCT ID | NCT06957626 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Colorectal Polyp |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-04-25 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-04-25 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The characteristics of the intestinal microbiota in high-risk colorectal polyp recurrence and their relationship with disease pathogenesis have not yet been fully elucidated. This study aims to analyze the microbial community characteristics in the intestinal mucosal tissue of patients after polypectomy with recurrence of colorectal polyps. Additionally, this research holds significant importance for understanding the etiology of adenoma recurrence and develop a microbiota and metabolite-based predicting tool.
Eligibility Criteria
Inclusion Criteria: * patients aged 40-75 years who undergo the colonoscopy with at least 1 advanced premalignant polyps or ≥ 3 adenoma Exclusion Criteria: * patient with severe physical diseases that prevented them from adhering to the examination requirements, * patient with coagulopathy or other contraindications for biopsy or polypectomy, * patient with previous surgical procedures on the gastrointestinal tract, * presence of colorectal cancer or other malignant tumor at baseline * presence of inflammatory bowel disease or hereditary polyposis syndromes (such as family adenomatous polyposis or Lynch syndrome) * within 1 month before enrollment, oral antibiotics and probiotics were taken; * inability to provide informed consent or refusal to participate in the study.
Contact & Investigator
Jing nan Li, MD, Ph.D
STUDY CHAIR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT06957626 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Colorectal Polyp. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06957626 currently recruiting?
Yes, NCT06957626 is actively recruiting participants. Contact the research team at pengchengf@mail.sdu.edu.cn for enrollment information.
Where is the NCT06957626 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06957626 clinical trial?
NCT06957626 is sponsored by Peking Union Medical College Hospital. The principal investigator is Jing nan Li, MD, Ph.D at Peking Union Medical College Hospital. The trial plans to enroll 150 participants.